BTK: a two-faced effector in cancer and tumour suppression.pdf (305.59 kB)
Download file

BTK: a two-faced effector in cancer and tumour suppression.

Download (305.59 kB)
journal contribution
posted on 25.07.2019, 14:38 by Miran Rada, Nickolai Barlev, Salvador Macip
Many genes of the human genome display pleiotropic activity, playing an important role in two or more unrelated pathways. Surprisingly, some of these functions can even be antagonistic, often letting to divergent functional outcomes depending on microenviromental cues and tissue/cell type-dependent parameters. Lately, the Bruton's tyrosine kinase (BTK) has emerged as one of such pleiotropic genes, with opposing effects in cancer pathways. While it has long been considered oncogenic in the context of B cell malignancies, recent data shows that BTK can also act as a tumour suppressor in other cells, as an essential member of the p53 and p73 responses to damage. Since BTK inhibitors are already being used clinically, it is important to carefully review these new findings in order to fully understand the consequences of blocking BTK activity in all the cells of the organism.

Funding

N.B. acknowledges the grant support from the Russian Government Program for the Recruitment of the leading scientists into the Russian Institutions of Higher Education 14.W03.31.0029.

History

Citation

Cell Death & Disease, 2018, 9, Article number: 1064

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/Biological Sciences/Molecular & Cell Biology

Version

VoR (Version of Record)

Published in

Cell Death & Disease

Publisher

Springer Nature for Associazione Differenziamento e Morte Cellulare

eissn

2041-4889

Acceptance date

01/10/2018

Copyright date

2018

Available date

25/07/2019

Publisher version

https://www.nature.com/articles/s41419-018-1122-8

Language

en

Usage metrics

Categories

Keywords

Licence

Exports